Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2012, Article ID 209567, 8 pages
http://dx.doi.org/10.1155/2012/209567
Research Article

Propyl Gallate Plays a Nephroprotective Role in Early Stage of Diabetic Nephropathy Associated with Suppression of Glomerular Endothelial Cell Proliferation and Angiogenesis

1Department of Nephrology, Renmin Hospital, Hubei University of Medicine, Hubei, Shiyan 442000, China
2Clinic Medicine Research Institute, Renmin Hospital, Hubei University of Medicine, Hubei, Shiyan 442000, China
3Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Hubei, Shiyan 442000, China

Received 18 May 2012; Revised 9 July 2012; Accepted 10 July 2012

Academic Editor: A. Veves

Copyright © 2012 Shaojiang Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Chiarelli, S. Gaspari, and M. L. Marcovecchio, “Role of growth factors in diabetic kidney disease,” Hormone and Metabolic Research, vol. 41, no. 8, pp. 585–593, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Rossing and D. de Zeeuw, “Need for better diabetes treatment for improved renal outcome,” Kidney international. Supplement, no. 120, pp. S28–S32, 2011. View at Google Scholar · View at Scopus
  3. T. Nakagawa, T. Kosugi, M. Haneda, C. J. Rivard, and D. A. Long, “Abnormal angiogenesis in diabetic nephropathy,” Diabetes, vol. 58, no. 7, pp. 1471–1478, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Saito, Y. Maeshima, T. Nasu et al., “Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis,” American Journal of Physiology, vol. 300, no. 4, pp. 873–886, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Tremolada, R. Lattanzio, G. Mazzolari, and G. Zerbini, “The therapeutic potential of VEGF inhibition in diabetic microvascular complications,” American Journal of Cardiovascular Drugs, vol. 7, no. 6, pp. 393–398, 2007. View at Google Scholar · View at Scopus
  6. J. Shields and A. P. Maxwell, “Managing diabetic nephropathy,” Clinical Medicine, Journal of the Royal College of Physicians of London, vol. 10, no. 5, pp. 500–504, 2010. View at Google Scholar · View at Scopus
  7. J. Karalliedde and G. Viberti, “Proteinuria in diabetes: bystander or pathway to cardiorenal disease?” Journal of the American Society of Nephrology, vol. 21, no. 12, pp. 2020–2027, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. J. Li, S. J. Kwak, D. S. Jung et al., “Podocyte biology in diabetic nephropathy,” Kidney International, vol. 72, no. 106, pp. S36–S42, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Nakagawa, “Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease,” American Journal of Physiology, vol. 292, no. 6, pp. F1665–F1672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Tian, Y. Gan, J. Li et al., “Imbalance of glomerular VEGF-NO axis in diabetic rats: prevention by chronic therapy with propyl gallate,” Journal of Nephrology, vol. 24, no. 4, pp. 499–506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Kalluri and V. P. Sukhatme, “Fibrosis and angiogenesis,” Current Opinion in Nephrology and Hypertension, vol. 9, no. 4, pp. 413–418, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Sanz, P. Santos-Valle, V. Alonso-Camino et al., “Long-term in vivo imaging of human angiogenesis: critical role of bone marrow-derived mesenchymal stem cells for the generation of durable blood vessels,” Microvascular Research, vol. 75, no. 3, pp. 308–314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Kučera and E. Lammert, “Ancestral vascular tube formation and its adoption by tumors,” Biological Chemistry, vol. 390, no. 10, pp. 985–994, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. H. P. Hammes, “Pericytes and the pathogenesis of diabetic retinopathy,” Hormone and Metabolic Research, vol. 37, supplement 1, pp. S39–S43, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Izquierdo, J. D. Cañete, R. Celis et al., “Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy,” PloS ONE, vol. 4, no. 12, p. e8131, 2009. View at Google Scholar · View at Scopus
  16. T. Nakagawa, “A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism,” Clinical Nephrology, vol. 71, no. 2, pp. 103–109, 2009. View at Google Scholar · View at Scopus
  17. K. Doi, E. Noiri, and T. Fujita, “Role of vascular endothelial growth factor in kidney disease,” Current Vascular Pharmacology, vol. 8, no. 1, pp. 122–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. H. J. Baelde, M. Eikmans, D. W. P. Lappin et al., “Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss,” Kidney International, vol. 71, no. 7, pp. 637–645, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Satoh, S. Fujimoto, Y. Haruna et al., “NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy,” American Journal of Physiology, vol. 288, no. 6, pp. F1144–F1152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Khamaisi, S. Keynan, M. Bursztyn et al., “Role of renal nitric oxide synthase in diabetic kidney disease during the chronic phase of diabetes,” Nephron, vol. 102, no. 3-4, pp. p72–p80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. M. L. Onozato, A. Tojo, A. Goto, T. Fujita, and C. S. Wilcox, “Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB,” Kidney International, vol. 61, no. 1, pp. 186–194, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Keynan, B. Hirshberg, N. Levin-Iaina et al., “Renal nitric oxide production during the early phase of experimental diabetes mellitus,” Kidney International, vol. 58, no. 2, pp. 740–747, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Ishii, K. P. Patel, P. H. Lane et al., “Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus,” Journal of the American Society of Nephrology, vol. 12, no. 8, pp. 1630–1639, 2001. View at Google Scholar · View at Scopus
  24. S. J. Shin, F. J. Lai, J. D. Wen et al., “Neuronal and endothelial nitric oxide synthase expression in outer medulla of streptozotocin-induced diabetic rat kidney,” Diabetologia, vol. 43, no. 5, pp. 649–659, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. X. L. Du, D. Edelstein, S. Dimmeler, Q. Ju, C. Sui, and M. Brownlee, “Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site,” Journal of Clinical Investigation, vol. 108, no. 9, pp. 1341–1348, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Tadano, S. Morimoto, F. Takahashi-Yanaga, Y. Miwa, I. Ohtsuki, and T. Sasaguri, “Propyl gallate, a strong antioxidant, increases the ca2+ sensitivity of cardiac myofilament,” Journal of Pharmacological Sciences, vol. 109, no. 3, pp. 456–458, 2009. View at Publisher · View at Google Scholar · View at Scopus